CGEN vs. SGMO

In the year-to-date period, CGEN achieves a 37.25% return, which is significantly higher than SGMO's 4.90% return. Over the past 10 years, CGEN has outperformed SGMO with an annualized return of -13.42%, while SGMO has yielded a comparatively lower -23.97% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Compugen Ltd. (CGEN) and Sangamo Therapeutics, Inc. (SGMO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current CGEN Sharpe Ratio is -0.17, which is lower than the SGMO Sharpe Ratio of -0.06. The chart below compares the historical Sharpe Ratios of CGEN and SGMO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither CGEN nor SGMO has paid dividends to shareholders.

The maximum CGEN drawdown since its inception was -97.90%, roughly equal to the maximum SGMO drawdown of -99.40%. Use the drawdown chart below to compare losses from any high point for CGEN and SGMO. For additional features, visit the drawdowns tool.

Compugen Ltd. (CGEN) has a higher volatility of 19.56% compared to Sangamo Therapeutics, Inc. (SGMO) at 18.29%. This indicates that CGEN's price experiences larger fluctuations and is considered to be riskier than SGMO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Compugen Ltd. and Sangamo Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.